2255 related articles for article (PubMed ID: 28810809)
1. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
2. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
[TBL] [Abstract][Full Text] [Related]
3. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells.
Baek HJ; Kim JS; Yoon M; Lee JJ; Shin MG; Ryang DW; Kook H; Kim SK; Cho D
Anticancer Res; 2013 May; 33(5):2011-9. PubMed ID: 23645750
[TBL] [Abstract][Full Text] [Related]
5. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
[TBL] [Abstract][Full Text] [Related]
6. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.
Granzin M; Soltenborn S; Müller S; Kollet J; Berg M; Cerwenka A; Childs RW; Huppert V
Cytotherapy; 2015 May; 17(5):621-32. PubMed ID: 25881519
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo expansion of natural killer cells for clinical applications.
Klingemann HG; Martinson J
Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
[TBL] [Abstract][Full Text] [Related]
8. [Method for expansion in vitro of CD3-CD56+CD16+NK cells highly purified from human peripheral blood].
Xiong D; Yang ZG; Li QH; Wu ZC; Lü JT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1310-5. PubMed ID: 21129283
[TBL] [Abstract][Full Text] [Related]
9. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood.
Condiotti R; Zakai YB; Barak V; Nagler A
Exp Hematol; 2001 Jan; 29(1):104-13. PubMed ID: 11164111
[TBL] [Abstract][Full Text] [Related]
11. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells.
Moseman JE; Foltz JA; Sorathia K; Heipertz EL; Lee DA
Cytotherapy; 2020 Jun; 22(6):322-328. PubMed ID: 32278551
[TBL] [Abstract][Full Text] [Related]
13. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56
Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K
Front Immunol; 2021; 12():640672. PubMed ID: 34017328
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
15. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
16. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21.
Kweon S; Phan MT; Chun S; Yu H; Kim J; Kim S; Lee J; Ali AK; Lee SH; Kim SK; Doh J; Cho D
Front Immunol; 2019; 10():879. PubMed ID: 31105701
[No Abstract] [Full Text] [Related]
17. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
18. Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential.
van Ostaijen-ten Dam MM; Prins HJ; Boerman GH; Vervat C; Pende D; Putter H; Lankester A; van Tol MJ; Zwaginga JJ; Schilham MW
J Immunother; 2016; 39(2):90-100. PubMed ID: 26849078
[TBL] [Abstract][Full Text] [Related]
19. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
20. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.
Lock D; Mockel-Tenbrinck N; Drechsel K; Barth C; Mauer D; Schaser T; Kolbe C; Al Rawashdeh W; Brauner J; Hardt O; Pflug N; Holtick U; Borchmann P; Assenmacher M; Kaiser A
Hum Gene Ther; 2017 Oct; 28(10):914-925. PubMed ID: 28847167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]